CN106029140A - 吸入器 - Google Patents
吸入器 Download PDFInfo
- Publication number
- CN106029140A CN106029140A CN201580010117.0A CN201580010117A CN106029140A CN 106029140 A CN106029140 A CN 106029140A CN 201580010117 A CN201580010117 A CN 201580010117A CN 106029140 A CN106029140 A CN 106029140A
- Authority
- CN
- China
- Prior art keywords
- inhaler device
- base
- base plate
- amino
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims abstract description 57
- 239000002775 capsule Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- -1 Acrylate Butadiene benzene Ethylene Chemical group 0.000 description 69
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 52
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 18
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 18
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 18
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 14
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- 150000002118 epoxides Chemical class 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229950005498 triparanol Drugs 0.000 description 7
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- DTZDZCNXNYMMOW-UHFFFAOYSA-N 9-hydroxyxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3OC2=C1 DTZDZCNXNYMMOW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 3
- ZMXHONJJTQSZKY-UHFFFAOYSA-N 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C(F)=CC=1C(O)(C(=O)O)C1=CC=C(F)C(F)=C1 ZMXHONJJTQSZKY-UHFFFAOYSA-N 0.000 description 2
- RCORMCWYMRPHPO-UHFFFAOYSA-N 2,2-bis(3-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=CC(F)=CC=1C(O)(C(=O)O)C1=CC=CC(F)=C1 RCORMCWYMRPHPO-UHFFFAOYSA-N 0.000 description 2
- YKZXWNCXGVYCKF-UHFFFAOYSA-N 2,2-bis(4-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)O)C1=CC=C(F)C=C1 YKZXWNCXGVYCKF-UHFFFAOYSA-N 0.000 description 2
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 2
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229950001653 cilomilast Drugs 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 2
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- QAIOVDNCIZSSSF-RFAJLIJZSA-N etiprednol dicloacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@@H]2O QAIOVDNCIZSSSF-RFAJLIJZSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229950001737 meluadrine Drugs 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 1
- YVAIFZYQODGYQY-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)CNC2=C1 YVAIFZYQODGYQY-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- MAGCRYYXZYUDSY-UHFFFAOYSA-N 2-fluoro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(F)(C(=O)O)C1=CC=CC=C1 MAGCRYYXZYUDSY-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- XZJRPNSAGRIIHL-UHFFFAOYSA-N 7-methoxyquinazolin-2-amine Chemical compound C1=NC(N)=NC2=CC(OC)=CC=C21 XZJRPNSAGRIIHL-UHFFFAOYSA-N 0.000 description 1
- XMOAAORIXBPOCZ-UHFFFAOYSA-N 9-(difluoromethyl)xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(C(F)F)C3=CC=CC=C3OC2=C1 XMOAAORIXBPOCZ-UHFFFAOYSA-N 0.000 description 1
- ZRDOWGBNGIHJTG-UHFFFAOYSA-N 9-(hydroxymethyl)xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(CO)(C(O)=O)C3=CC=CC=C3OC2=C1 ZRDOWGBNGIHJTG-UHFFFAOYSA-N 0.000 description 1
- QPVQJRWUNUHSJL-UHFFFAOYSA-N 9-ethylxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(CC)(C(O)=O)C3=CC=CC=C3OC2=C1 QPVQJRWUNUHSJL-UHFFFAOYSA-N 0.000 description 1
- CBNOKZSYCBHRAD-UHFFFAOYSA-N 9-methylxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C)(C(O)=O)C3=CC=CC=C3OC2=C1 CBNOKZSYCBHRAD-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- SRJDFSRXQHFSBO-UHFFFAOYSA-N acetic acid;methylcyclopropane Chemical compound CC1CC1.CC(O)=O SRJDFSRXQHFSBO-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 229950006944 atizoram Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229950001167 butixocort Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- HSDBULQDKRYING-UHFFFAOYSA-N cyclopropyltropine benzilate Chemical compound C1C(C2C3C2)N(C)C3CC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HSDBULQDKRYING-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950006990 etiprednol dicloacetate Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- 229950008319 flutropium bromide Drugs 0.000 description 1
- FNUZASGZEHGWQM-RJRMRWARSA-M flutropium bromide Chemical compound C[N@+](CCF)([C@H](CC1)C2)[C@@H]1C[C@H]2OC(C(C1=CC=CC=C1)(C1=CC=CC=C1)O)=O.[Br-] FNUZASGZEHGWQM-RJRMRWARSA-M 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- RFHABUQANXJNQS-UHFFFAOYSA-N methyl 9h-xanthene-9-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)C3=CC=CC=C3OC2=C1 RFHABUQANXJNQS-UHFFFAOYSA-N 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950010289 soterenol Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- SYHDSBBKRLVLFF-UHFFFAOYSA-N triparanol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC(C)=CC=1)CC1=CC=C(Cl)C=C1 SYHDSBBKRLVLFF-UHFFFAOYSA-N 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
一种吸入器装置,包括:外壳(2),覆盖所述外壳(2)的底板(4),与所述底板(4)一体化的药物储存器(10),位于所述底板(4)上方的吸口(3),覆盖所述吸口(3)的盖(1),至少一个穿刺元件(11),致动部件(5),弹簧(12),其特征在于所述吸入器装置为两铰链系统(6,8),其中所述底板(4)连接至铰链(6);所述吸口(3)和所述盖(1)连接至铰链(8)。
Description
技术领域
本发明涉及一种用于吸入胶囊中所含有的粉末状药物组合物的吸入装置,所述胶囊插入于该吸入装置的药物储存器中。
背景技术
吸入装置的发明为治疗和管理呼吸系统疾病铺设了一条无障碍的道路。现今干粉吸入装置在靶向给药至受影响的肺呼吸道领域中发挥着重要的作用。自1967年干粉吸入器(DPI)已经面世,Aventis第一个开发名为SPINHALER的DPI用于递送色甘酸钠。自此,在吸入装置的设计和使用方面观察到许多改进。
通常粉末吸入装置用于从胶囊吸入单剂量或多剂量的粉剂药物。该装置配置为具有容纳含有粉剂药物的胶囊的药物储存器。在吸入过程中,具有穿刺机制的装置刺穿胶囊,使药物能够分散到使用者吸入的空气中。空的胶囊保留在装置中,然后在下次使用该装置之前将其丢弃。
US 3,807,400公开了具有涡流室的吸入装置中的一些改进,装置在它们本身已知的基本操作中可以被考虑,且旨在分散填充有粉末状药物组合物的胶囊的内容物。根据本发明的装置提供了为伸缩结构的吸口和两个按照径向相对位置放置在可转的部件中且由该部件驱动的穿刺装置,当延伸时伸缩结构形成涡流室,后面提到的部件的壁炉架形成有能够向两个穿刺装置提供一些穿刺操作的凸轮。
US 8,006,695描述了用于从可刺穿的胶囊吸入药物的吸入器装置,该吸入器装置包括用于容纳医药胶囊的外壳;用于封闭外壳的封闭工具,所述封闭装置相对于外壳可以移动;适合于刺穿医药胶囊的穿刺工具;其中封闭装置相对于外壳的移动引起穿刺装置的移动。本发明还提供了用于医药胶囊的储存器,该医药储存器包括适用于容纳医药胶囊的腔室;和用于在通过该腔室的液体流中产生湍流的工具,在使用中,湍流的液体流引起由腔室容纳的胶囊的振动以帮助释放胶囊中所含有的药物。
US 7,694,676描述了一种用于从胶囊吸入粉末状药物组合物的吸入器,该吸入器包含:下部;可以锁至下部上的板,用该板可以将下部封闭;用于容纳胶囊的胶囊储存器,该储存器适于降入下部;可锁至该板的吸口;通过封闭元件在封闭位置覆盖并锁住吸口的盖,下部、板、吸口和盖通过单一接头铰接在一起。
US 8,022,082公开了一种吸入器,包括:含有两个窗口的外壳,其中具有进气口且设有由屏幕外壳固定的屏幕的平面,连接至具有按钮的平面的吸入室,该吸入室具有两个尖锐与弹簧相反地可移动的针,连接至外壳、平面和通过轴使它能够翻开和关闭的盖的吸口和三个在围绕胶囊室的中心区且在屏幕外壳及屏幕的下面、直径小于1mm的孔。
US 7,252,087公开了一种利用多功能致动部件的吸入器。如在US‘087中公开的多功能致动部件在第一功能位置允许封闭元件脱离外壳的下部,且在第二功能位置允许吸口转离外壳的下部。
US 7,284,553公开了一种根据伯努利原理操作的粉末吸入器。它公开了一种具有胶囊室的吸入器,该吸入器包含胶囊室的内表面上或者胶囊的外表面上的凸起元件。
尽管现有技术讨论了许多不同种类的用于递送药物的吸入器,本领域仍然需要基于影响治疗依从性的因素,如待递送的药物、便于操作和患者的偏好设计和开发改善的用于粉末吸入剂递送的吸入器。因此本发明旨在通过在它们的操作方面进一步改善已知的吸入器来充分解决本领域中已有的这些和其它需要。
因此,本发明涉及具有两铰链系统、旨在分散粉末状药物组合物的内容物的改进的吸入装置。
在干粉吸入器的正常使用中,患者打开盖,然后打开吸口,并插入含有粉末状药物组合物的胶囊。然后患者按压致动部件,导致刺穿含有粉末状药物组合物的胶囊。连接至致动部件的穿刺元件从一侧刺穿胶囊,使得当患者从吸口吸入时胶囊中含有的粉末状药物组合物出来。
本发明的吸入器中的“两铰链”设计采用了两个单独的铰链。一个铰链用于盖和吸口且第二个铰链用于底板。当需要时患者只需要打开底板。第二个不同的铰链的使用防止底板意外打开,从而避免药物的污染。此外,非突出的致动部件使装置的操作和储存非常方便。
此外,吸入器的形状在整个顶部和一侧为圆形,吸入器的形状以一定的角度配置,以这种方式患者能适当地握住该装置且发现在握住装置期间很方便开动装置且不会失去控制。
发明目的
本发明的目的为克服现有技术的缺陷。
本发明的另一个目的为提供具有两铰链系统(6,8)的吸入器装置。
本发明的另一个目的为提供具有两铰链系统的吸入器装置,其中吸口(3)和盖(1)连接至一个铰链(8)
本发明的另一个目的为提供具有两铰链系统的吸入器装置,其中底板(4)与吸口和盖分开铰接至铰链(6)。
本发明的另一个目的为提供使用不具有任何孔的底板(4)的吸入器。
本发明的另一个目的为提供吸入器,其中握持辅助物(9)设置在致动部件(5)的远端。
发明内容
根据本发明的一个方面,提供了一种吸入器装置,包括外壳(2),覆盖所述外壳(2)的底板(4),与所述底板(4)一体化的药物储存器(10),位于所述底板(4)上方的吸口(3),覆盖所述吸口(3)的盖(1),至少一个穿刺元件(11),致动部件(5),弹簧(12),其特征在于所述吸入器装置为两铰链系统(6,8),其中所述底板(4)连接至铰链(6);所述吸口(3)和所述盖(1)连接至铰链(8)。
附图说明
图1说明了根据本发明的吸入器的基本组件,其中外壳(2)容纳底板(4)并被底板(4)、吸口(3)和握持辅助物(9)所覆盖。底板(4)连接至铰链(6),吸口(3)和盖(1)不同于底板一起铰接至铰链(8)。握持辅助物(9)设置在致动部件(5)的远端。
图2说明了安装在底板(4)下面的药物储存器(10)的顶视图。
图3说明了位于与药物储存器(10)一体化的底板(4)上方的吸口(3)的封闭视图。两个铰链(6,8)不同地标记。
图4说明了吸入器的径向局部剖视图,其描绘了盖(1)、吸口(3)、穿刺元件(11)、致动部件(5)、弹簧(12)、药物储存器(10)、观察窗(7)以及连接至铰链(8)的吸口和盖。
图5说明了在完全封闭状态下吸入器的侧视图。
图6说明了不具有任何孔的吸入器底板(4)的俯视图。
图7说明了具有不同的两个铰链系统(6,8)的吸入器。
图8说明了在本发明的吸入器中压力差的平方根对流速的曲线图,描绘了相对高的空气流动阻力。
具体实施方式
下面给出本发明的简化概要以提供对本发明的一些方面的基本理解。此概述并非本发明的广泛综述。它并不旨在确定本发明的关键/重要要素或描绘本发明的范围。其唯一的目的在于作为稍后给出的本发明的更详细的描述的前奏以简化的形式给出本发明的一些概念。
根据本发明,提供了一种用于从胶囊吸入粉末状药物组合物的吸入器,所述胶囊在使用之前插入该吸入器中设置的药物储存器中。根据本发明,在将胶囊插入该装置的药物储存器之后,患者可以按压致动部件,致动部件可以从静止位置被移动,从而与至少一个可以进入药物储存器的穿刺元件共同作用。胶囊被一个穿刺元件的最小部分刺穿,药物组合物释放。
从以下详细的描述结合本发明的附图、公开的示例性实施方式,本发明的其它方面、优势和突出的特点对本领域技术人员来说将变得明显。
如图1、2、3和4所示,根据本发明的吸入器基本上由容纳底板(4)并被底板(4)覆盖的外壳(2)、具有握持辅助物(9)的吸口(3)组成;所述底板(4)连接至铰链(6),吸口(3)和盖(1)不同于底板一起铰接至铰链(8);握持辅助物(9)设置在致动部件(5)的远端。观察窗(7)还允许观察装置的内部元件。药物储存器(10)安装在底板(4)的下面。从致动部件(5)的内部连接一个以上用于刺穿胶囊的穿刺元件(11)且弹簧(12)也配置成连接致动部件;特征在于当从外部按压致动器时,弹簧元件(12)被压缩并使穿刺元件(11)能够线性移动并刺穿胶囊以便释放胶囊内部的药物且之后弹簧元件缩回。
在以下描述和权利要求书中所用的术语和词汇不局限于书目含义,而仅被发明人使用以能够清楚和一致理解本发明。
盖子(1)通过防止进入灰尘或任何其它外来颗粒为装置组件提供保护。
吸口(3)为患者通过它来吸入粉末状药物组合物的组件。
底板(4)确保牢固地保持药物储存器(10)且为了药物的平稳流动药物储存器(10)始终保持对齐吸口(3)。
致动部件(5)负责锁定和开启盖(1)并将穿刺元件(11)保持在适当的位置。当向上移动致动部件(5)时,确保适当刺穿胶囊,以这种方式粉末状药物组合物可以被患者吸入。
铰链(6)负责将底板保持在适当的位置,以这种方式药物储存器(10)总是对齐吸口(3)。
观察窗(7)提供药物储存器(10)的观察,使患者确定胶囊存在于药物储存器(10)中。
铰链(8)负责盖(1)和吸口(3)的适当移动。
吸口上的握持辅助物(9)为患者提供了打开吸口(3)的手柄以便含有粉末状药物组合物的胶囊可能被放入药物储存器(10)中。
在本发明的一个实施方式中,以以下方式操作吸入器。
a)通过按压致动部件(5)打开盖(1)
b)盖(1)被向上拉起并远离底板以暴露吸口(3)
c)通过拉位于吸口(3)两侧的握持辅助物(9)将吸口(3)打开
d)将胶囊放进本发明的吸入器的药物储存器(10)中
e)关紧吸口(3)。盖(1)保持打开
f)本发明的吸入器被保持在吸口(3)指向上的位置
g)按压致动部件(5)以移动穿刺元件(11)刺穿胶囊
h)从胶囊吸入粉末状药物组合物。
装置可以由任何合适的材料制成。优选地装置由塑料,例如ABS(丙烯酸丁二烯苯乙烯)、PC(聚碳酸酯)、PA(聚缩醛)或PS(聚苯乙烯)或其混合物制成,或者由抗静电材料(迭尔林或不锈钢)制成。
相比于现有技术已知的装置,根据本发明的吸入器允许更可靠地递送药物组合物。
本发明的吸入器的优点如下:
1.当需要时患者只需要打开底板。使用第二个不同的铰链防止底板的意外打开,从而避免污染药物。
2.而且,非突出的致动部件使装置的操作和装置的储存非常方便。
3.此外,吸入器的形状在整个顶部和一侧为圆形,吸入器的形状以一定的角度配置,以这种方式患者能适当地握住该装置且发现在握住装置期间很方便开动装置且不会失去控制。
测量具有两个铰链系统、使用不具有任何孔的底板的吸入器装置的流动阻力为约0.07/Lmin-1,从而产生约40L min-1的流动速率且从吸入器的一边到另一边的压力差为约4kPa。
利用下式可以计算流动阻力:R=P0.5/Q
其中Q为流动速率(L/min),P为从吸入器的一边到另一边的压力差(kPa)且R为流动阻力[kPa0.5/(L/min)]。
在该系统中,在2kpa和6kpa之间的吸入压力差产生每分钟约25至55升之间的合成流速。
本发明涉及如上所述的吸入器装置在通过吸入给予粉末状药物组合物中的应用,所述粉末状药物组合物适用于治疗哮喘或慢性阻塞性肺疾病。
压力差对流速的曲线取决于吸入器的结构。
对根据本发明的吸入器进行测试以测量其流动阻力,流动阻力为吸入器的重要特性。
根据伯努利原理,当以压力差的平方根对流速作图时,吸入器的阻力为曲线的线性部分的斜率。在图8中可以看出针对根据本发明的吸入器装置的示例图。图8中所示的图表明了相对高的气流阻力,曲线随流速快速增加。
根据本发明的吸入器可以包含根据不同的粉剂药物具有不同的特性这一认识提供的设计特征。因此,为了提高递送效率,应针对待递送的具体药物有利地调节吸入器的流动参数。这些调节可以通过调节气流来进行。气流可以通过钻额外的供气孔或通过增加或减小供气孔的开口尺寸来控制。
优选的,胶囊中含有的粉末状药物组合物为干燥的粉剂药物。术语胶囊旨在进行广义地理解并包含对于粉末状药物组合物任何合适的容器。胶囊可以由任何合适的材料,包含明胶、HPMC或塑料来形成。
在一个实施方式中,本发明提供了包含可以通过吸入给药的粉剂药物的药物组合物。关于这点特别优选的是选自抗胆碱能类药物、β-2激动剂、类固醇、PDE IV-抑制剂、LTD4拮抗剂和EGFR-激酶抑制剂之中的药物组合物。
供使用的抗胆碱能类药物优选地选自任选地其外消旋体、对映体或非对映体形式和任选地其溶剂化物和/或水合物的形式的噻托溴铵、氧托溴铵、氟托溴铵、异丙托溴铵、格隆盐(glycopyrronium salts)、曲司氯铵、托特罗定、托品2,2-二苯基丙酸酯甲溴化物、东莨菪醇2,2-二苯基丙酸酯甲溴化物、东莨菪醇2-氟-2,2-二苯基乙酸酯甲溴化物、托品2-氟-2,2-二苯基乙酸酯甲溴化物、托品3,3',4,4'-四氟三苯乙醇酯甲溴化物(tropenol3,3',4,4'-tetrafluorobenzilate methobromide)、东莨菪醇3,3',4,4'-四氟三苯乙醇酯甲溴化物(scopine 3,3',4,4'-tetrafluorobenzilate methobromide)、托品4,4'-二氟三苯乙醇酯甲溴化物(tropenol 4,4'-difluorobenzilate methobromide)、东莨菪醇4,4'-二氟三苯乙醇酯甲溴化物(scopine 4,4'-difluorobenzilate methobromide)、托品3,3'-二氟三苯乙醇酯甲溴化物(tropenol3,3'-difluorobenzilate methobromide)、东莨菪醇3,3'-二氟三苯乙醇酯甲溴化物(scopine3,3'-difluorobenzilate methobromide)、托品9-羟基-芴-9-羧酸酯甲溴化物、托品9-氟-芴-9-羧酸酯甲溴化物、东莨菪醇9-羟基-芴-9-羧酸酯甲溴化物、东莨菪醇9-氟-芴-9-羧酸酯甲溴化物、托品9-甲基-芴-9-羧酸酯甲溴化物、东莨菪醇9-甲基-芴-9-羧酸酯甲溴化物、环丙基托品三苯乙醇酯甲溴化物(cyclopropyltropine benzilate methobromide)、2,2-二苯基丙酸酯环丙基托品甲溴化物、环丙基托品9-羟基-氧杂蒽-9-羧酸酯甲溴化物、环丙基托品9-甲基-芴-9-羧酸酯甲溴化物、环丙基托品-9-甲基-氧杂蒽-9-羧酸酯甲溴化物、环丙基托品9-羟基-芴-9-羧酸酯甲溴化物、甲基4,4'-二氟三苯乙醇酯环丙基托品甲溴化物、托品9-羟基-氧杂蒽-9-羧酸酯甲溴化物、东莨菪醇9-羟基-氧杂蒽-9-羧酸酯甲溴化物、托品9甲基-氧杂蒽-9-羧酸酯甲溴化物、东莨菪醇9-甲基-氧杂蒽-9-羧酸酯甲溴化物、托品9-乙基-氧杂蒽-9-羧酸酯甲溴化物、托品9-二氟甲基-氧杂蒽-9-羧酸酯甲溴化物和东莨菪醇9-羟甲基-氧杂蒽-9-羧酸酯甲溴化物之中。
所采用的β-2激动剂优选地选自任选地其外消旋体、对映体或非对映体形式和任选地其药理学上可接受的酸加成盐、溶剂化物和/或水合物的形式的沙丁胺醇、班布特罗、比托特罗、溴沙特罗、卡布特罗、克仑特罗、非诺特罗、福莫特罗、海索那林、异丁特罗、新异丙肾上腺素、异丙肾上腺素、左旋沙丁胺醇、马布特罗、美卢君(meluadrine)、奥西那林、间羟异丙肾上腺素、吡布特罗、丙卡特罗、瑞普特罗、利米特罗、利托君、沙美特罗、沙甲胺醇、索特瑞醇(soterenot)、沙丰特罗(sulphonterol)、噻拉米特、特布他林、妥鲁特罗、CHF-1035、HOKU-81、KUL-1248、3-(4-{6-[2-羟基-2-(4-羟基-3-羟甲基-苯基)-乙氨基]-己基-氧基}-丁基)-苯磺酰胺、5-[2-(5,6-二乙基-茚满-2-基氨基)-1-羟基-乙基]-8-羟基-1H-喹啉-2-酮、4-羟基-7-[2-{[2-{[3-(2-苯基乙氧基)丙基]磺酰基}乙基]-氨基}乙基]-2(3H)-苯并噻唑酮、1-(2-氟-4-羟基苯基)-2-[4-(1-苯并咪唑基)-2-甲基-2-丁基氨基]乙醇、1-[3-(4-甲氧基苄基-氨基)-4-羟基苯基]-2-[4-(1-苯并咪唑基)-2-甲基-2-丁基氨基]乙醇、1-[2H-5-羟基-3-氧代-4H-1,4-苯并恶嗪-8-基]-2-[3-(4-N,N-二甲氨基苯基)-2-甲基-2-丙氨基]乙醇、1-[2H-5-羟基-3-氧代-4H-1,4-苯并恶嗪-8-基]-2-[3-(4-甲氧基苯基)-2-甲基-2-丙氨基]乙醇、1-[2H-5-羟基-3-氧代-4H-1,4-苯并恶嗪-8-基]-2-[3-(4-正丁氧基苯基)-2-甲基-2-丙氨基]乙醇、1-[2H-5-羟基-3-氧代-4H-1,4-苯并恶嗪-8-基]-2-{4-[3-(4-甲氧苯基)-1,2,4-三唑-3-基]-2-甲基-2-丁氨基}乙醇、5-羟基-8-(1-羟基-2-异丙基氨基丁基)-2H-1,4-苯并恶嗪-3-(4H)-酮、1-(4-氨基-3-氯-5-三氟甲基苯基)-2-叔丁基氨基)乙醇和1-(4-乙氧基羰基氨基-3-氰基-5-氟苯基)-2-(叔丁基氨基)-乙醇之中。
所采用的类固醇类优选地选自任选地其外消旋体、对映体或非对映体形式和任选地其药理学上可接受的酸加成盐、溶剂化物和/或水合物的形式的泼尼松龙、泼尼松、布替可特丙酸酯(butixocortpropionate)、RPR-106541、氟尼缩松、倍氯米松、曲安西龙、布地奈德、氟替卡松、莫米松、环索奈德、罗氟奈德、ST-126、地塞米松、(S)-氟代甲基6.正交.,9.正交.-二氟代-17.正交.-[(2-呋喃基羰基)氧基]-11.正交.-羟基-16.正交.-甲基-3-氧代-雄甾-1,4-二烯-17.正交.-硫代羧酸酯((S)-fluoromethyl6.quadrature.,9.quadrature.-difluoro-17.quadrature.-[(2-furanylcarbonyl)oxy]-11.quadrature.-hydroxy-16.quadrature.-methyl-3-oxo-androsta-1,4-diene-17.quadrature.-carbothionate)、(S)-(2-氧代-四氢-呋喃-3S-基)6.正交.,9.正交.-二氟代-11.正交.-羟基-16.正交.-甲基-3-氧代-17.正交.-丙酰氧基-雄甾-1,4-二烯-17.正交.-硫代羧酸酯((S)-(2-oxo-tetrahydro-furan-3S-yl)6.quadrature.,9.quadrature.-difluoro-11.quadrature.-hydroxy-16.quadrature.-methyl-3-oxo-17.quadrature.-propionyloxy-androsta-1,4-diene-17.quadratur-e.-carbothionate)和艾泼诺酯(etiprednol-dichloroacetate,BNP-166)之中。
所采用的PDE IV抑制剂优选地选自任选地其外消旋体、对映体或非对映体形式和任选地其药理学上可接受的酸加成盐、其溶剂化物和/或水合物的形式的恩丙茶碱、茶碱、罗氟司特、西洛司特(cilomilast)、CP-325,366、BY343、D-4396(Sch-351591)、AWD-12-281(GW-842470)、N-(3,5-二氯-1-氧代-吡啶-4-基)-4-二氟甲氧基-3-环丙基甲氧基苯甲酰胺、NCS-613、普马芬汀(pumafentine)、(-)对-[(4aR*,10bS*)-9-乙氧基-1,2,3,4,4a,10b-六氢-8-甲氧基-2-甲基苯并[s][1,6]萘啶-6-基]-N,N-二异丙基苯甲酰胺、(R)-(+)-1-(4-溴苄基)-4-[(3-环戊氧基)-4-甲氧苯基]-2-吡咯烷酮、3-(环戊氧基-4-甲氧基苯基)-1-(4-N'-[N-2-氰基-S-甲基-异硫脲基]苄基)-2-吡咯烷酮、顺式[4-氰基-4-(3-环戊氧基-4-甲氧苯基)环己烷-1-羧酸]、2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1-酮、顺式[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1--醇]、(R)-(+)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]乙酸酯、(S)-(-)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2--亚基]乙酸酯、CDP840、Bay-198004、D-4418、PD-168787、T-440、T-2585、沙罗茶碱(arofyllin)、阿替佐南(atizoram)、V-11294A、CI-1018、CDC-801、CDC-3052、D-22888、YM-58997、Z-15370、9-环戊基-5,6-二氢-7-乙基-3-(2-噻吩基)-9H-吡唑并[3,4-c]-1,2,4--三唑并[4,3-a]吡啶和9-环戊基-5,6-二氢-7-乙基-3-(叔丁基)-9H-吡唑并[3,4-c]-1,2,4-三唑并[4,3-a]吡啶之中。
所采用的LTD4拮抗剂优选地选自任选地其外消旋体、对映体或非对映体形式,任选地其药理学上可接受的酸加成盐的形式以及任选地其盐和衍生物、其溶剂化物和/或水合物的形式的孟鲁司特,1-(((R)-(3-(2-(6,7-二氟-2-喹啉基)乙烯基)苯基)-3-(2-(2-羟基--2-丙基)苯基)硫代)甲基环丙烷乙酸,1-(((1(R)-3(3-(2-(2,3-二氯噻吩并[3,2-b]吡啶-5-基)-(E)-乙烯基)苯基)-3-(2-(1-羟基-1-甲基乙基)苯基)丙基)硫代)甲基)环丙乙酸,普仑司特,扎鲁司特,[2-[[2-(4-叔丁基-2-噻唑基)-5-苯并呋喃基]氧基甲基]苯基]乙酸,MCC-847(ZD-3523),MN-001,MEN-91507(LM-1507),VUF-5078,VUF-K-8707和L-733321之中。
所采用的EGFR-激酶抑制剂优选地选自任选地其外消旋体、对映体或非对映体形式和任选地其药理学上可接受的酸加成盐、其溶剂化物和/或水合物的形式的西妥昔单抗、曲妥单抗、ABX-EGF、Mab ICR-62、4-[(3-氯-4-氟苯基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉、4-[(R)-(1-苯基-乙基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]-氨基}-7-环戊氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{[4-((R)-6-甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-[(S)-(四氢呋喃-3-基)氧基]-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[2-((S)-6-甲基-2-氧代-吗啉-4-基)-乙氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟苯基)氨基]-6-({4-[N-(2-甲氧基-乙基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉、4-[(R)-(1-苯基-乙基)氨基]-6-({4-[N-(四氢吡喃-4-基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉、4-[(3-氯-4-氟苯基)氨基]-6-({4-[N-(2-甲氧基-乙基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环戊氧基-喹唑啉、4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-[(R)-(四氢呋喃-2-基)甲氧基]喹唑啉、4-[(3-乙炔基-苯基)氨基]-6,7-双-(2-甲氧基-乙氧基)-喹唑啉、4-[(R)-(1-苯基-乙基)氨基]-6-(4-羟基-苯基)-7H-吡咯并[2,3-d]嘧啶、3-氰基-4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-乙氧基-喹啉、4-[(R)-(1-苯基-乙基)氨基]-6-{[4-((R)-6-甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟苯基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-[(四氢呋喃-2-基)甲氧基]喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-{[4-(5,5-二甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{2-[4-(2-氧代-吗啉-4-基)-哌啶-1-基]-乙氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-氨基-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-甲磺酰胺基-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-3-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(吗啉-4-基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(哌啶-3-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[1-(2-乙酰氨基-乙基)-哌啶-4-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-4-基氧基)-7-乙氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{反式-4-[(吗啉-4-基)羰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(哌啶-1-基)羰基]-哌啶-4-基氧基}-7-甲氧基喹唑啉、4-[(3-氯-4-氟苯基)氨基]-6-(顺式-4-{N-[(吗啉-4-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-乙磺酰胺基-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲磺酰基-哌啶-4-基氧基)-7-(2-甲氧基-乙氧基)-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[1-(2-甲氧基-乙酰基)-哌啶-4-基氧基]-7-(2-甲氧基-乙氧基)-喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-(四氢吡喃-4-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(顺式-4-{N-[(哌啶-1-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{顺式-4-[(吗啉-4-基)羰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{1-[2-(2-氧代吡咯烷-1-基)乙基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-(1-乙酰基哌啶-4-基氧基)-7-甲氧基-喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-(1-甲基-哌啶-4-基氧基)-7-甲氧基-喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-(1-甲磺酰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲基-哌啶-4-基氧基)-7-(2-甲氧基-乙氧基)-喹唑啉、4-[(3-乙炔基-苯基)氨基]-6-{1-[(吗啉-4-基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(N-甲基-N-2-甲氧基乙基-氨基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(1-乙基-哌啶-4-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[顺式-4-(N-甲磺酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[顺式-4-(N-乙酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-甲基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[反式-4-(N-甲磺酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-二甲氨基-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(反式-4-{N-[(吗啉-4-基)碳基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-[2-(2,2-二甲基-6-氧代-吗啉-4-基)-乙氧基]-7-[(S)-(四氢呋喃-2-基)甲氧基]-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲磺酰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)氨基]-6-(1-氰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉和4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(2-甲氧乙基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉之中。
酸加成盐(使用药理学上可接受的酸能够形成该化合物)的示例包括选自盐酸盐、氢溴酸盐、氢碘酸盐、硫酸氢盐、磷酸氢盐、甲磺酸氢盐、硝酸氢盐、马来酸氢盐、醋酸氢盐、苯酸氢盐、柠檬酸氢盐、富马酸氢盐、酒石酸氢盐、草酸氢盐、琥珀酸氢盐、苯酸氢盐和对甲苯磺酸氢盐之中的盐,优选地选自盐酸盐、氢溴酸盐、硫酸氢盐、磷酸氢盐、富马酸氢盐和甲磺酸氢盐之中的盐。
粉末状药物组合物可以含有上述活性物质及其盐、酯,或者这些活性物质、盐、酯的组合。
尽管在本文中参考具体的实施方式对发明进行了描述,但可以理解的是,这些实施方式仅是说明了本发明的原理和应用。因此,可以理解的是,在不脱离本发明的精神和范围的情况下,对示例性的实施方式可以作出许多修改且可以设计其他安排。
Claims (13)
1.一种吸入器装置,包括:
-外壳(2)、
-覆盖所述外壳(2)的底板(4)、
-与所述底板(4)一体化的药物储存器(10)、
-位于所述底板(4)上方的吸口(3)、
-覆盖所述吸口(3)的盖(1)、
-至少一个穿刺元件(11)、
-致动部件(5)、
-弹簧(12),
其特征在于所述吸入器装置为两铰链系统(6,8),其中
-所述底板(4)连接至铰链(6),
-所述吸口(3)和所述盖(1)连接至铰链(8)。
2.根据权利要求1所述的吸入器装置,其中所述底板(4)与所述吸口(3)和盖(1)分开铰接。
3.根据权利要求1所述的吸入器装置,其中从所述致动部件(5)的内部连接所述穿刺元件(11)。
4.根据权利要求1所述的吸入器装置,其中所述弹簧(12)配置为连接所述致动部件(5)。
5.根据权利要求4所述的吸入器装置,其中为了辅助穿刺,当按压所述致动部件(5)时,所述致动部件(5)导致所述弹簧元件(12)被压缩,使得所述穿刺元件(11)能够线性移动。
6.根据权利要求1所述的吸入器装置,其中所述装置还包括所述吸口(3)上的握持辅助物(9),所述握持辅助物(9)提供了用于打开所述吸口(3)的握持件。
7.根据权利要求1所述的吸入器装置,其中所述装置还包括观察到所述吸入器装置的对面的观察窗(7)。
8.根据权利要求6所述的吸入器装置,其中所述握持辅助物(9)设置在所述致动部件(5)的远端。
9.根据权利要求1所述的吸入器装置,其中将所述药物储存器(10)安装在所述底板(4)的下面。
10.根据权利要求1所述的吸入器装置,其中所述底板不具有任何孔。
11.根据权利要求1所述的吸入器装置,其中将所述药物储存器(10)设计为含有胶囊,所述胶囊具有粉末状药物组合物。
12.根据权利要求11所述的吸入器装置,其中所述粉末状药物组合物适用于通过吸入治疗哮喘或慢性阻塞性肺疾病。
13.根据权利要求11所述的吸入器装置,其中所述胶囊中含有的所述粉末状药物组合物为干燥的粉剂药物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN663/MUM/2014 | 2014-02-25 | ||
PCT/IB2015/051350 WO2015128789A1 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
IN663MU2014 IN2014MU00663A (zh) | 2014-02-25 | 2015-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106029140A true CN106029140A (zh) | 2016-10-12 |
CN106029140B CN106029140B (zh) | 2019-07-05 |
Family
ID=52697485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580010117.0A Active CN106029140B (zh) | 2014-02-25 | 2015-02-23 | 吸入器 |
Country Status (17)
Country | Link |
---|---|
US (1) | US10556069B2 (zh) |
EP (1) | EP3110483B1 (zh) |
JP (1) | JP6509894B2 (zh) |
CN (1) | CN106029140B (zh) |
AU (1) | AU2015221812B2 (zh) |
CA (1) | CA2939310C (zh) |
ES (1) | ES2714566T3 (zh) |
HU (1) | HUE042087T2 (zh) |
IN (1) | IN2014MU00663A (zh) |
MX (1) | MX2016011003A (zh) |
MY (1) | MY180735A (zh) |
PH (1) | PH12016501659A1 (zh) |
PL (1) | PL3110483T3 (zh) |
PT (1) | PT3110483T (zh) |
RU (1) | RU2655131C2 (zh) |
UA (1) | UA117517C2 (zh) |
WO (1) | WO2015128789A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113813479A (zh) * | 2021-08-19 | 2021-12-21 | 石小慧 | 一种储备式哮喘病人自主上药用噻托溴铵粉上药器 |
CN113926031A (zh) * | 2021-11-16 | 2022-01-14 | 石小慧 | 一种哮喘病人上药用噻托溴铵粉上药器 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA169756S (en) | 2016-02-08 | 2017-09-01 | Nicoventures Holdings Ltd | Electronic cigarette |
GB201605105D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision apparatus |
GB201605101D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Electronic vapour provision system |
GB201605102D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Mechanical connector for electronic vapour provision system |
GB201605100D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision system |
WO2018015712A1 (en) | 2016-07-22 | 2018-01-25 | Nicoventures Holdings Limited | Case for a vapour provision device |
DE202017102334U1 (de) | 2016-08-25 | 2017-11-29 | Alfred Von Schuckmann | Vorrichtung zum Inhalieren pulverförmiger Substanzen |
USD831190S1 (en) * | 2016-11-08 | 2018-10-16 | Alfred Von Schuckmann | Inhaler |
USD849927S1 (en) * | 2017-08-17 | 2019-05-28 | Alfred Von Schuckmann | Inhaler |
PL234586B1 (pl) * | 2017-08-31 | 2020-03-31 | Pulinno Spolka Z Ograniczona Odpowiedzialnoscia | Inhalator pojedynczej dawki suchego proszku |
US20190076607A1 (en) * | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
US11730898B2 (en) * | 2017-10-24 | 2023-08-22 | Merxin Ltd | Inhaler |
AU201815816S (en) * | 2018-04-04 | 2018-10-30 | Chia Tai Tianqing Pharmaceutical Group Co | Inhaler |
USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
USD983354S1 (en) | 2020-12-21 | 2023-04-11 | Rpc Formatec Gmbh | Inhaler |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060237016A1 (en) * | 2005-04-22 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dry powder inhaler |
CN2915141Y (zh) * | 2006-07-06 | 2007-06-27 | 福建精致模具有限公司 | 一种胶囊型干粉吸入器 |
WO2012047182A2 (en) * | 2010-10-07 | 2012-04-12 | Mahmut Bilgic | Single dose dry powder inhalation device |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT941426B (it) | 1971-07-17 | 1973-03-01 | Isf Spa | Inalatore a camera di turbinio per sostanze medicamentose polveriformi |
US20030235538A1 (en) | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
DE10352277A1 (de) | 2003-11-08 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator |
DE602005019604D1 (de) | 2004-11-10 | 2010-04-08 | Cipla Ltd | Inhalator |
WO2008001744A1 (en) * | 2006-06-27 | 2008-01-03 | Otsuka Pharmaceutical Co., Ltd. | Powder inhaler |
DE102006045788A1 (de) * | 2006-09-26 | 2008-03-27 | Alfred Von Schuckmann | Spender für pulverförmige Massen |
GB2492035B (en) * | 2010-04-23 | 2014-03-05 | Cambridge Consultants | Dry powder inhaler assembly and containers |
EA026450B1 (ru) * | 2011-11-25 | 2017-04-28 | Махмут Билджик | Ингалятор |
DE102012103482A1 (de) * | 2012-04-20 | 2013-10-24 | Alfred Von Schuckmann | Vorrichtung zum Inhalieren pulverförmiger Substanzen |
ZA201408393B (en) * | 2013-11-19 | 2015-11-25 | Cipla Ltd | Inhaler device |
-
2015
- 2015-02-23 PL PL15711296T patent/PL3110483T3/pl unknown
- 2015-02-23 MY MYPI2016702930A patent/MY180735A/en unknown
- 2015-02-23 HU HUE15711296A patent/HUE042087T2/hu unknown
- 2015-02-23 ES ES15711296T patent/ES2714566T3/es active Active
- 2015-02-23 WO PCT/IB2015/051350 patent/WO2015128789A1/en active Application Filing
- 2015-02-23 PT PT15711296T patent/PT3110483T/pt unknown
- 2015-02-23 JP JP2016554637A patent/JP6509894B2/ja active Active
- 2015-02-23 US US15/121,430 patent/US10556069B2/en active Active
- 2015-02-23 RU RU2016137683A patent/RU2655131C2/ru active
- 2015-02-23 UA UAA201609743A patent/UA117517C2/uk unknown
- 2015-02-23 CN CN201580010117.0A patent/CN106029140B/zh active Active
- 2015-02-23 AU AU2015221812A patent/AU2015221812B2/en active Active
- 2015-02-23 MX MX2016011003A patent/MX2016011003A/es active IP Right Grant
- 2015-02-23 IN IN663MU2014 patent/IN2014MU00663A/en unknown
- 2015-02-23 CA CA2939310A patent/CA2939310C/en active Active
- 2015-02-23 EP EP15711296.2A patent/EP3110483B1/en active Active
-
2016
- 2016-08-19 PH PH12016501659A patent/PH12016501659A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060237016A1 (en) * | 2005-04-22 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dry powder inhaler |
CN2915141Y (zh) * | 2006-07-06 | 2007-06-27 | 福建精致模具有限公司 | 一种胶囊型干粉吸入器 |
WO2012047182A2 (en) * | 2010-10-07 | 2012-04-12 | Mahmut Bilgic | Single dose dry powder inhalation device |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113813479A (zh) * | 2021-08-19 | 2021-12-21 | 石小慧 | 一种储备式哮喘病人自主上药用噻托溴铵粉上药器 |
CN113813479B (zh) * | 2021-08-19 | 2023-12-01 | 丰都县中医院 | 一种储备式哮喘病人自主上药用噻托溴铵粉上药器 |
CN113926031A (zh) * | 2021-11-16 | 2022-01-14 | 石小慧 | 一种哮喘病人上药用噻托溴铵粉上药器 |
CN113926031B (zh) * | 2021-11-16 | 2023-08-15 | 南京茂升德科技有限公司 | 一种哮喘病人上药用噻托溴铵粉上药器 |
Also Published As
Publication number | Publication date |
---|---|
EP3110483B1 (en) | 2018-12-19 |
MY180735A (en) | 2020-12-08 |
RU2016137683A3 (zh) | 2018-03-29 |
PH12016501659B1 (en) | 2016-10-03 |
MX2016011003A (es) | 2016-11-30 |
EP3110483A1 (en) | 2017-01-04 |
US20160375207A1 (en) | 2016-12-29 |
HUE042087T2 (hu) | 2019-06-28 |
RU2655131C2 (ru) | 2018-05-23 |
IN2014MU00663A (zh) | 2015-09-25 |
RU2016137683A (ru) | 2018-03-29 |
ES2714566T3 (es) | 2019-05-29 |
WO2015128789A1 (en) | 2015-09-03 |
CN106029140B (zh) | 2019-07-05 |
AU2015221812B2 (en) | 2019-12-19 |
JP2017510343A (ja) | 2017-04-13 |
UA117517C2 (uk) | 2018-08-10 |
PL3110483T3 (pl) | 2019-06-28 |
JP6509894B2 (ja) | 2019-05-08 |
US10556069B2 (en) | 2020-02-11 |
CA2939310A1 (en) | 2015-09-03 |
AU2015221812A1 (en) | 2016-09-08 |
PT3110483T (pt) | 2019-03-21 |
PH12016501659A1 (en) | 2016-10-03 |
CA2939310C (en) | 2022-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106029140B (zh) | 吸入器 | |
CN103272730B (zh) | 雾化器 | |
TWI571277B (zh) | 粉末吸入器 | |
CN101754780B (zh) | 粉末吸入器 | |
BRPI0610140A2 (pt) | nebulizador | |
AU2008281704B2 (en) | Inhaler | |
DE102006016903A1 (de) | Inhalator | |
DE102006017699A1 (de) | Inhalator | |
CN101309715A (zh) | 用于穿刺吸入粉末胶囊的针 | |
DE102006016904A1 (de) | Inhalator | |
TW201004663A (en) | Inhaler | |
DE102006016901A1 (de) | Mundstück für einen Inhalator | |
TW200911311A (en) | Inhaler | |
JP5566576B2 (ja) | 吸入器用ブリスタ | |
EP2373366B1 (de) | Inhalator | |
JP2012510324A5 (zh) | ||
BR112016019649B1 (pt) | Dispositivo de inalação | |
JP4825455B2 (ja) | 粉末吸入器 | |
CN101410147A (zh) | 具有最佳化排空性质的用于多剂量粉末吸入器的包装 | |
AU2012202119A1 (en) | Blister for inhalers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1227333 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |